Chagas disease (CD) is a parasitic, systemic, chronic, and often fatal illness caused by
infection with the protozoan Trypanosoma cruzi. The World Health Organization classifies …

Trypanosoma cruzi, the protozoan causative of Chagas disease (ChD), exhibits striking
genetic and phenotypic intraspecific diversity, along with ecoepidemiological complexity …

Chronic Trypanosoma cruzi infections are typically lifelong, with small numbers of parasites
surviving in restricted tissue sites, which include the gastrointestinal tract. There is …

Benznidazole is the front-line drug used to treat infections with Trypanosoma cruzi, the
causative agent of Chagas disease. However, for reasons that are unknown, treatment …

Trypanosoma cruzi is a remarkably versatile parasite. It can parasitize almost any nucleated
cell type and naturally infects hundreds of mammal species across much of the Americas. In …

Introduction Chagas disease affects 6–7 million people, mainly in the Americas, and
benznidazole is one of the two therapeutic options available. Trypanocide treatment aims to …

For nearly all eukaryotic cells, stochastic DNA double-strand breaks (DSBs) are one of the
most deleterious types of DNA lesions. DSB processing and repair can cause sequence …

Leucine, isoleucine, and valine, collectively termed Branched Chain Amino Acids (BCAA),
are hydrophobic amino acids (AAs) and are essential for most eukaryotes since in these …

Trypanosoma cruzi is the protozoan that causes Chagas disease (CD), an endemic
parasitosis in Latin America distributed around the globe. If CD is not treated in acute phase …

Trypanosoma cruzi uses various mechanisms of infection to access humans. Since 1967,
food contaminated with metacyclic trypomastigotes has triggered several outbreaks of acute …